Literature DB >> 8306241

A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms.

G Chouinard1, L Annable, L Turnier, N Holobow, N Szkrumelak.   

Abstract

This double-blind clinical trial studied 16 acutely agitated psychotic patients with manic or manic-like symptoms who needed rapid tranquilization and were therefore on maintenance treatment. They were randomized to receive intramuscular preparations of clonazepam (1 to 2 mg) or haloperidol (5 to 10 mg) at 0, 0.5, and 1.0 hours. Both medications produced significant reduction of manic symptoms within two hours of initial treatment; however, haloperidol produced beneficial results more rapidly than clonazepam. All patients completed the study, with the exception of one haloperidol-treated patient who developed severe parkinsonism. It was concluded that I.M. clonazepam is an effective, safe, but slower-acting alternative to I.M. haloperidol in the treatment of agitated psychiatric patients in need of rapid tranquilization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306241

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  16 in total

1.  A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.

Authors:  B K Yee; R Keist; L von Boehmer; R Studer; D Benke; N Hagenbuch; Y Dong; R C Malenka; J-M Fritschy; H Bluethmann; J Feldon; H Möhler; U Rudolph
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-11       Impact factor: 11.205

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 4.  Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Melanie J Brooke-Powney; Xue Li; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

Review 5.  Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.

Authors:  R B Belgamwar; M Fenton
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 6.  The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.

Authors:  Guy Chouinard
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

Review 7.  Pharmacological treatment of psychotic agitation.

Authors:  Glenn W Currier; Adam Trenton
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Pharmacological management of agitation in emergency settings.

Authors:  A Yildiz; G S Sachs; A Turgay
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

Review 9.  Benzodiazepines for schizophrenia.

Authors:  Markus Dold; Chunbo Li; Magdolna Tardy; Vesal Khorsand; Donna Gillies; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

10.  Respiratory arrest and oversedation in an adolescent given intramuscular clonazepam for rapid tranquillization.

Authors:  Jonathan Channing; Simon Hill; Marion Wetherill; Oliver White
Journal:  Ther Adv Psychopharmacol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.